You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
苑東生物(688513.SH)預計年度純利增加56.52%-70.33%
格隆匯 01-10 14:59

格隆匯1月10日丨苑東生物(688513.SH)公佈,公司預計2020年年度實現歸屬於母公司所有者的淨利潤為17,000萬元到18,500萬元,與上年同期相比,將增加6,138.84萬元到7,638.84萬元,同比增加56.52%到70.33%。

公司預計2020年年度歸屬於母公司所有者的扣除非經常性損益的淨利潤為10,800萬元到12,300萬元,與上年同期相比,將增加2,014.37萬元到3,514.37萬元,同比增加22.93%到40.00%。

淨利潤同比上升主要原因:1、富馬酸比索洛爾片第一順位中標國家藥品集中帶量採購導致銷量增加;布洛芬注射液銷售增長以及新產品依託考昔片及注射用帕瑞昔布鈉等上市銷售所致。2、本報吿期收到的與收益相關的政府補助增加以及上年度股份支付影響等導致非經常性損益較上年同期增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account